Cargando…
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination
We describe a case of second primary malignancy in a 65-year-old patient affected by polycythemia vera treated with the JAK 1/2 inhibitor ruxolitinib. The latter is recognized as a risk factor for the onset of non-melanoma skin cancers in many retrospective and perspective studies, but the concomita...
Autores principales: | Masucci, Chiara, Passucci, Mauro, Scalzulli, Emilia, Carmosino, Ida, Capriata, Marcello, Costa, Alessandro, Ielo, Claudia, Martelli, Maurizio, Breccia, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282638/ https://www.ncbi.nlm.nih.gov/pubmed/37350945 http://dx.doi.org/10.3389/fonc.2023.1212638 |
Ejemplares similares
-
Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023) -
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort
por: Scalzulli, Emilia, et al.
Publicado: (2022) -
Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016) -
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
por: Sakiyama, Emiko, et al.
Publicado: (2020) -
Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma
por: Buonerba, Luciana, et al.
Publicado: (2020)